BR9908188A - Preparação farmacêutica, uso de um agonista de receptor de tipo 2 de angiotensina ii ou de um seu sal fisiologicamente aceitável, e, processo para tratamento e/ou prevenção de uma afecção selecionada do grupo consistindo de distúrbios do trato alimentar, tais como dispepsia, sìndrome de intestino irritável e/ou insuficiência múltipla de órgãos em um paciente - Google Patents

Preparação farmacêutica, uso de um agonista de receptor de tipo 2 de angiotensina ii ou de um seu sal fisiologicamente aceitável, e, processo para tratamento e/ou prevenção de uma afecção selecionada do grupo consistindo de distúrbios do trato alimentar, tais como dispepsia, sìndrome de intestino irritável e/ou insuficiência múltipla de órgãos em um paciente

Info

Publication number
BR9908188A
BR9908188A BR9908188-1A BR9908188A BR9908188A BR 9908188 A BR9908188 A BR 9908188A BR 9908188 A BR9908188 A BR 9908188A BR 9908188 A BR9908188 A BR 9908188A
Authority
BR
Brazil
Prior art keywords
angiotensin
type
dyspepsia
patient
multiple organ
Prior art date
Application number
BR9908188-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Lars Fondriks
Anders Pettersson
Anders Hallberg
Original Assignee
A & Science Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A & Science Invest Ab filed Critical A & Science Invest Ab
Publication of BR9908188A publication Critical patent/BR9908188A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9908188-1A 1998-02-24 1999-02-24 Preparação farmacêutica, uso de um agonista de receptor de tipo 2 de angiotensina ii ou de um seu sal fisiologicamente aceitável, e, processo para tratamento e/ou prevenção de uma afecção selecionada do grupo consistindo de distúrbios do trato alimentar, tais como dispepsia, sìndrome de intestino irritável e/ou insuficiência múltipla de órgãos em um paciente BR9908188A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9800550A SE9800550D0 (sv) 1998-02-24 1998-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
PCT/SE1999/000262 WO1999043339A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof

Publications (1)

Publication Number Publication Date
BR9908188A true BR9908188A (pt) 2000-10-24

Family

ID=20410283

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908188-1A BR9908188A (pt) 1998-02-24 1999-02-24 Preparação farmacêutica, uso de um agonista de receptor de tipo 2 de angiotensina ii ou de um seu sal fisiologicamente aceitável, e, processo para tratamento e/ou prevenção de uma afecção selecionada do grupo consistindo de distúrbios do trato alimentar, tais como dispepsia, sìndrome de intestino irritável e/ou insuficiência múltipla de órgãos em um paciente

Country Status (18)

Country Link
EP (1) EP1066048A1 (es)
JP (1) JP2002504516A (es)
KR (1) KR20010041211A (es)
CN (1) CN1291104A (es)
AU (1) AU755949B2 (es)
BR (1) BR9908188A (es)
CA (1) CA2319123A1 (es)
EE (1) EE200000481A (es)
HU (1) HUP0101411A3 (es)
ID (1) ID26639A (es)
IL (1) IL137990A0 (es)
IS (1) IS5594A (es)
MX (1) MXPA00008172A (es)
NO (1) NO20004215L (es)
NZ (1) NZ506188A (es)
SE (1) SE9800550D0 (es)
SK (1) SK11522000A3 (es)
WO (1) WO1999043339A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393755C (en) * 1999-12-16 2010-09-21 The University Of Southern California Methods for treating and preventing damage to mucosal tissue
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
AU2002257970B2 (en) 2001-05-31 2007-08-02 Vicore Pharma Ab Tricyclic compounds useful as angiotensin II agonists
MX2007012635A (es) 2005-04-12 2008-01-11 Vicore Pharma Ab Nuevos agonistas de angiotensina ii triciclica.
EP1869009B1 (en) 2005-04-12 2016-06-01 Vicore Pharma AB New bicyclic angiotensin ii agonists
CA2604797C (en) 2005-04-12 2013-05-28 Vicore Pharma Ab New tricyclic angiotensin ii agonists
EP1968635B1 (en) * 2005-12-14 2014-09-17 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
US20150119329A1 (en) * 2012-04-16 2015-04-30 New York University Modulation of angiotensin ii receptors for the prevention and treatment of malaria cerebral
MX2017010993A (es) 2015-03-02 2018-04-11 Vicore Pharma Ab Agonista del receptor de angiotensina ii para tratar la fibrosis pulmonar.
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
JP2022542437A (ja) 2019-08-02 2022-10-03 ランティオペプ ベスローテン ヴェンノーツハップ 癌の処置に用いるアンジオテンシン２型（ａｔ２）受容体アゴニスト
GB201913603D0 (en) 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
CA3175559A1 (en) 2020-03-19 2021-09-23 Vicore Pharma Ab Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii
GB202004094D0 (en) 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202006081D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202013721D0 (en) 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
GB202104033D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB202104038D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
WO2022200785A1 (en) 2021-03-23 2022-09-29 Vicore Pharma Ab Selective angiotensin ii receptor ligands
CA3222721A1 (en) 2021-07-09 2023-01-12 Nadia Nasser PETERSEN New selective angiotensin ii compounds
GB202115303D0 (en) 2021-10-25 2021-12-08 Vicore Pharma Ab New formulation
WO2023152503A1 (en) 2022-02-10 2023-08-17 Vicore Pharma Ab Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444067A (en) * 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
AU3708295A (en) * 1994-11-04 1996-05-31 Stefan L. Marklund Use of receptor agonists to stimulate superoxide dismutase activity
SE9501881D0 (sv) * 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII-receptor antagonists
US5834432A (en) * 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
SE9502219D0 (sv) * 1995-06-19 1995-06-19 Astra Ab Novel medical use

Also Published As

Publication number Publication date
NO20004215D0 (no) 2000-08-23
JP2002504516A (ja) 2002-02-12
AU2753799A (en) 1999-09-15
HUP0101411A2 (hu) 2002-03-28
CA2319123A1 (en) 1999-09-02
NO20004215L (no) 2000-09-18
EE200000481A (et) 2002-02-15
SE9800550D0 (sv) 1998-02-24
HUP0101411A3 (en) 2002-11-28
CN1291104A (zh) 2001-04-11
MXPA00008172A (es) 2002-06-21
AU755949B2 (en) 2003-01-02
WO1999043339A1 (en) 1999-09-02
EP1066048A1 (en) 2001-01-10
SK11522000A3 (sk) 2001-04-09
NZ506188A (en) 2003-04-29
KR20010041211A (ko) 2001-05-15
IL137990A0 (en) 2001-10-31
ID26639A (id) 2001-01-25
IS5594A (is) 2000-08-21

Similar Documents

Publication Publication Date Title
BR9908188A (pt) Preparação farmacêutica, uso de um agonista de receptor de tipo 2 de angiotensina ii ou de um seu sal fisiologicamente aceitável, e, processo para tratamento e/ou prevenção de uma afecção selecionada do grupo consistindo de distúrbios do trato alimentar, tais como dispepsia, sìndrome de intestino irritável e/ou insuficiência múltipla de órgãos em um paciente
Nimmo et al. Pharmacological modification of gastric emptying: effects of propantheline and metoclopromide on paracetamol absorption
Schilström et al. Nicotine and food induced dopamine release in the nucleus accumbens of the rat: putative role of α7 nicotinic receptors in the ventral tegmental area
Bremell et al. Outbreak of spontaneous staphylococcal arthritis and osteitis in mice
Richards et al. The influence of muscle flap coverage on the repair of devascularized tibial cortex: an experimental investigation in the dog
E BURKE Heterotopic bone formation in thermal burns
Kavaliers et al. IgG from antiserum against endogenous mammalian FMRF-NH2-related peptides augments morphine-and stress-induced analgesia in mice
Plumet et al. Bacteriophage therapy for Staphylococcus aureus infections: a review of animal models, treatments, and clinical trials
AU645023B2 (en) Compositions and method for treating painful, inflammatory or allergic disorders
JPH04235135A (ja) 医薬組成物
BRPI0317463B8 (pt) composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
Andrews et al. Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: a review of supporting neurochemical and behavioural evidence
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR0112661A (pt) Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
BR9713141A (pt) Composição farmcêutica processo e kit para o tratamento ou a prevenção de um quadro fisiológico asociado com um distúrbio isquêmico relacionado com trombose e um paciente, uso de quantidades farmaceuticamente efetivas de um composto com atividade anti-xa e de um composto antagonista de agregação de plaquetas, produto contendo estes compostos, e, uso destes compostos.
Shanks et al. Norepinephrine and serotonin alterations following chronic stressor exposure: mouse strain differences
Nutt et al. Adult night terrors and paroxetine
SE466889B (sv) Analgetiska och anti-inflammatoriska kompositioner bestaaende av ibuprofen och koffein
Wyatt Risks of withdrawing antipsychotic medications
Kruis et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis
Armbrecht et al. Capacity of 1, 25-dihydroxyvitamin D to stimulate expression of calbindin D changes with age in the rat
Griffin et al. Pauciarticular arthritis in children
US5929035A (en) Methods of treating intestinal disorders
US6544565B2 (en) Use of Valeriana for the treatment of Restless Leg Syndrome and related disorders
Meyendorff et al. Methylphenidate infusion in euthymic bipolars: effect of carbamazepine pretreatment

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: PHARMACORE AB (SE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTA A 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.